Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis.

Journal:

The Lancet. Global health, Volume: 7, Issue: 2

Published:

February 1, 2019

PMID:

30683238

Authors:

Gian Luca Di Tanna GL, Ali Raza Khaki AR, Grant Theron G, Kerrigan McCarthy K, Helen Cox H, Lucy Mupfumi L, Anete Trajman A, Lynn Sodai Zijenah LS, Peter Mason P, Tsitsi Bandason T, Betina Durovni B, Wilbert Bara W, Michael Hoelscher M, Petra Clowes P, Chacha Mangu C, Duncan Chanda D, Alexander Pym A, Peter Mwaba P, Frank Cobelens F, Mark P Nicol MP, Keertan Dheda K, Gavin Churchyard G, Katherine Fielding K, John Z Metcalfe JZ

Access Paper

DOI: 10.1016/S2214-109X(18)30458-3

PMID: 30683238

Abstract:

Xpert MTB/RIF, the most widely used automated nucleic acid amplification test for tuberculosis, is available in more than 130 countries. Although diagnostic accuracy is well documented, anticipated improvements in patient outcomes have not been clearly identified. We performed an individual patient data meta-analysis to examine improvements in patient outcomes associated with Xpert MTB/RIF.

Courtesy of the U.S. National Library of Medicine